Angiogenex Inc Email Format
Biotechnology ResearchNew York, United States2-10 Employees
Angiogenex Inc is a biotechnology research company focused on the discovery and development of inhibitors targeting Id proteins to address unmet medical needs in oncology and ophthalmology. It has assembled enabling technologies and collaborates with researchers including Robert Benezra, Ph.D., and The Robert Benezra Lab at Sloan Kettering Institute to identify specific and potent small-molecule binders of Id. Id proteins are linked to the pathogenesis of certain cancers and diseases of the eye. The company’s lead development candidate, AGX-A, is being studied for cholangiocarcinoma and age-related macular degeneration. Angiogenex is headquartered in New York City. It operates with a small team.